RS58955B1 - Jedinjenje (6s,9as)-n-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamida - Google Patents
Jedinjenje (6s,9as)-n-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamidaInfo
- Publication number
- RS58955B1 RS58955B1 RS20190665A RSP20190665A RS58955B1 RS 58955 B1 RS58955 B1 RS 58955B1 RS 20190665 A RS20190665 A RS 20190665A RS P20190665 A RSP20190665 A RS P20190665A RS 58955 B1 RS58955 B1 RS 58955B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- azetidin
- prop
- pyrazino
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013267687 | 2013-12-25 | ||
| EP14873998.0A EP3088401B1 (en) | 2013-12-25 | 2014-12-22 | (6s,9as)-n-benzyl-6-((4-hydroxyphenyl)methyl)-4,7-dioxo-8-((6-(3-(piperazine-1-yl)azetidine-1-yl)pyridine-2-yl)methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino(2,1-c)(1,2,4)triazine-1-carboxamide compound |
| PCT/JP2014/083932 WO2015098853A1 (ja) | 2013-12-25 | 2014-12-22 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58955B1 true RS58955B1 (sr) | 2019-08-30 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190665A RS58955B1 (sr) | 2013-12-25 | 2014-12-22 | Jedinjenje (6s,9as)-n-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamida |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9174998B2 (https=) |
| EP (1) | EP3088401B1 (https=) |
| JP (1) | JP6085040B2 (https=) |
| KR (1) | KR102307053B1 (https=) |
| CN (1) | CN105873932B (https=) |
| AR (1) | AR098908A1 (https=) |
| AU (1) | AU2014371148B2 (https=) |
| BR (1) | BR112016013572B1 (https=) |
| CA (1) | CA2932435C (https=) |
| CL (1) | CL2016001419A1 (https=) |
| CY (1) | CY1122521T1 (https=) |
| DK (1) | DK3088401T3 (https=) |
| ES (1) | ES2728353T3 (https=) |
| HR (1) | HRP20190908T1 (https=) |
| HU (1) | HUE044541T2 (https=) |
| IL (1) | IL245961A0 (https=) |
| JO (1) | JO3809B1 (https=) |
| LT (1) | LT3088401T (https=) |
| ME (1) | ME03391B (https=) |
| MX (1) | MX365376B (https=) |
| MY (1) | MY173946A (https=) |
| PE (1) | PE20160932A1 (https=) |
| PH (1) | PH12016501079A1 (https=) |
| PL (1) | PL3088401T3 (https=) |
| PT (1) | PT3088401T (https=) |
| RS (1) | RS58955B1 (https=) |
| RU (1) | RU2669805C2 (https=) |
| SG (1) | SG11201604496YA (https=) |
| SI (1) | SI3088401T1 (https=) |
| SM (1) | SMT201900306T1 (https=) |
| TR (1) | TR201908392T4 (https=) |
| TW (1) | TWI681961B (https=) |
| UA (1) | UA116923C2 (https=) |
| WO (1) | WO2015098853A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| BR112017027227B1 (pt) * | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| CA2986999C (en) * | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| MX2022005056A (es) | 2019-10-29 | 2022-05-18 | Eisai R&D Man Co Ltd | Combinacion de un antagonista de pd-1, un inhibidor tirosina cinasa de vegfr/fgfr/ret y un inhibidor de cbp/beta-catenina para el tratamiento del cancer. |
| AR121544A1 (es) | 2020-03-12 | 2022-06-15 | 3 2 Pharma | Inhibidores de la vía de señalización por cbp / catenina y sus usos |
| WO2021183791A1 (en) | 2020-03-12 | 2021-09-16 | City Of Hope | Wnt/cbp/catenin signaling pathway inhibitors and uses thereof |
| US20230390296A1 (en) | 2020-10-30 | 2023-12-07 | Keio University | Novel treatment and prevention of sarcopenia-related diseases |
| US20240352020A1 (en) * | 2021-08-26 | 2024-10-24 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| MX2024002060A (es) * | 2021-09-08 | 2024-03-01 | Eisai R&D Man Co Ltd | Composicion farmaceutica para tratar tumores solidos. |
| CN116262120A (zh) * | 2021-12-13 | 2023-06-16 | 上海中医药大学 | 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
| JPWO2024209717A1 (https=) | 2023-04-06 | 2024-10-10 | ||
| WO2025174646A1 (en) * | 2024-02-12 | 2025-08-21 | Albert Einstein College Of Medicine | Inhibitors of beta-catenin c-terminal domain and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1444235B1 (en) * | 2001-10-12 | 2008-06-11 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7671054B1 (en) * | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| WO2009148192A1 (en) | 2008-06-06 | 2009-12-10 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
| CN102459271B (zh) * | 2009-04-15 | 2014-07-02 | Jw制药公司 | 回折模拟物的新化合物及其制备方法和用途 |
| CN103209982B (zh) * | 2010-10-14 | 2016-03-16 | Jw制药公司 | 反转模拟物的化合物、其制造方法及其用途 |
| US20140051706A1 (en) * | 2011-02-25 | 2014-02-20 | Prism Pharma Co., Ltd. | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja not_active Ceased
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active Active
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 SM SM20190306T patent/SMT201900306T1/it unknown
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
-
2019
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102307053B1 (ko) | (6S,9aS)-N-벤질-6-[(4-하이드록시페닐)메틸]-4,7-디옥소-8-(｛6-[3-(피페라진-1-일)아제티딘-1-일]피리딘-2-일｝메틸)-2-(프로프-2-엔-1-일)-옥타하이드로-1H-피라지노[2,1-c][1,2,4]트리아진-1-카복사미드 화합물 | |
| KR102505664B1 (ko) | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP6126319B1 (ja) | （６Ｓ，９ａＳ）−Ｎ−ベンジル−６−［（４−ヒドロキシフェニル）メチル］−４，７−ジオキソ−８−（｛６−［３−（ピペラジン−１−イル）アゼチジン−１−イル］ピリジン−２−イル｝メチル）−２−（プロプ−２−エン−１−イル）−オクタヒドロ−１Ｈ−ピラジノ［２，１−ｃ］［１，２，４］トリアジン−１−カルボキサミド化合物の結晶 | |
| KR102638678B1 (ko) | 헤테로시클릭 화합물 | |
| NZ713233A (en) | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease | |
| CN104640859A (zh) | 作为γ分泌酶调节剂的稠合三唑衍生物 | |
| JP2023502279A (ja) | Ｃｐｓ１を阻害するためのピペラジン化合物 | |
| WO2016027844A1 (ja) | テトラヒドロイミダゾ［１，５－ｄ］［１，４］オキサゼピン化合物 | |
| NZ720718B2 (en) | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| HK1222656B (en) | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazine-1-yl)azetidine-1-yl]pyridine-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound | |
| NZ713233B2 (en) | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND |